SCHEMBL5124068

SCHEMBL5124068

O=c1oc(=O)n(-c2ccccc2)c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
ATM Q13315 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MAPK1 P28482 1/20 0.52
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TSHR P16473 1/20 0.46
BRCA1 P38398 1/20 0.46
MAPK8 P45983 2/20 0.45
PGR P06401 4/20 0.45
MAPK9 P45984 1/20 0.44
GLA P06280 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
HPGD P15428 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28038182 0.86 KMT2A (0.41) KDM4EATML3MBTL1MAPK1KMT2A
SCHEMBL11849396 0.86 METAP2 (0.46) KDM4EATML3MBTL1MAPK1KMT2A
SCHEMBL10834564 0.82 MAPT (0.60) KDM4EL3MBTL1KMT2AALDH1A1HPGD
SCHEMBL26128587 0.80 MAT2A (0.55) L3MBTL1KMT2AMEN1MAPK8MAPK9
SCHEMBL30611290 0.80 MAT2A (0.51) ATMMAPK1MAPK8MAPK9PMM2
SCHEMBL29110301 0.80 MAT2A (0.51) ATMMAPK1MAPK8MAPK9PMM2
SCHEMBL30611304 0.80 MAT2A (0.55) L3MBTL1KMT2AMEN1MAPK8MAPK9
SCHEMBL5130586 0.80 ELANE (0.43) KDM4EL3MBTL1MAPK1KMT2AALDH1A1
SCHEMBL11016646 0.79 PLA2G10 (0.47) ALDH1A1CYP1A2PMM2LMNAMPI
SCHEMBL10982087 0.78 MAOB (0.55) L3MBTL1KMT2AMEN1CA9BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110511188-B Preparation method of 2-imino dihydro quinazolinone compound 烟台大学 2022-09-20 CN claimed
US-12365762-B2 Dispersant for coating system BASF SE (DE) 2025-07-22 US disclosed
US-12024595-B2 Polymer composition BASF SE (DE) 2024-07-02 US disclosed
CN-112867751-B Dispersants for coating systems 巴斯夫欧洲公司 2023-10-27 CN disclosed
EP-3215558-B1 NOVEL POLYMER COMPOSITIONS AND USE OF THESE POLYMER COMPOSITIONS AS DISPERSANTS BASF SE (DE) 2023-01-11 EP disclosed
EP-3837301-B1 POLYMER COMPOSITION BASF SE (DE) 2022-06-15 EP disclosed
US-20210347950-A1 POLYMER COMPOSITION BASF SE (DE) 2021-11-11 US disclosed
US-20210230362-A1 A DISPERSANT FOR COATING SYSTEM BASF SE (DE) 2021-07-29 US disclosed
CN-112912420-A Polymer composition 巴斯夫欧洲公司 2021-06-04 CN disclosed
CN-112867751-A Dispersants for coating systems 巴斯夫欧洲公司 2021-05-28 CN disclosed
US-20160102198-A1 NOVEL POLYMER DISPERSANTS BASF SE (DE) 2016-04-14 US disclosed
US-20150038640-A1 NOVEL POLYMER DISPERSANTS BASF SE (DE) 2015-02-05 US disclosed
US-20080139551-A1 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES AVANIR PHARMACEUTICALS (US) 2008-06-12 US disclosed
WO-2007038571-A2 PROLYL HYDROXYLASE ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-05 WO disclosed
US-5190956-A Certain N-substituted 3-oximino-2,4-dioxoquinolin-2,4-(1H)diones useful for treating viral infections SCHERING CORPORATION (US) 1993-03-02 US disclosed
US-5179107-A Herpes SCHERING CORPORATION (US) 1993-01-12 US disclosed
US-4604464-A Immunomodulatory 3-(substituted aminobenzoyl)-3,4-dihydrophthalazin-1(2H)-ones PENNWALT CORPORATION (US) 1986-08-05 US disclosed
US-4058532-A 1-Phenyl-3,4-dihydrocarbostyrils STERLING DRUG INC. (US) 1977-11-15 US disclosed
US-4049715-A 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols STERLING DRUG INC. (US) 1977-09-20 US disclosed
US-3994902-A Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds STERLING DRUG INC. (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139551-A1 TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES TNF, TNFRSF1A, TNFRSF9 KDM4E 4691/4885ATM 4475/4885L3MBTL1 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.